Table 2 Effectiveness of triptorelin therapy in reducing total IPSS (full analysis population)

LUTS at baseline (N = 277) and IPSS data at week 48 (N = 213)

Moderate to severe LUTS at baseline (N = 255) and IPSS data at week 48 (N = 194)

Moderate to severe LUTS at baseline with non-operated prostate cancer (N = 212) and IPSS data at week 48 (N = 194)